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Abstract
Renal cell carcinoma (RCC) is the most deadly of urological malignancies. Metastatic disease affects one third of patients at
diagnosis with a further third developing metastatic disease after extirpative surgery. Heterogeneity in the clinical course
ensures predicting metastasis is notoriously difficult, despite the routine use of prognostic clinico-pathological parameters
in risk stratification. With greater understanding of pathways involved in disease pathogenesis, a number of biomarkers
have been shown to have prognostic significance, including Ki67, p53, vascular endothelial growth factor receptor 1
(VEGFR1) and ligand D (VEGFD), SNAIL and SLUG. Previous pathway analysis has been from study of the primary tumour,
with little attention to the metastatic tumours which are the focus of targeted molecular therapies. As such, in this study
a tissue microarray from 177 patients with primary renal tumour, renal vein tumour thrombus and/or RCC metastasis has
been created and used with Automated Quantitative Analysis (AQUA) of immunofluorescence to study the prognostic
significance of these markers in locally advanced and metastatic disease. Furthermore, this has allowed assessment of
differential protein expression between the primary tumours, renal vein tumour thrombi and metastases. The results
demonstrate that clinico-pathological parameters remain the most significant predictors of cancer specific survival;
however, high VEGFR1 or VEGFD can predict poor cancer specific survival on univariate analysis for locally advanced and
metastatic disease. There was significantly greater expression of Ki67, p53, VEGFR1, SLUG and SNAIL in the metastases
compared with the primary tumours and renal vein tumour thrombi. With the exception of p53, these differences in protein
expression have not been shown previously in RCC. This confirms the importance of proliferation, angiogenesis and
epithelial to mesenchymal transition in the pathogenesis and metastasis of RCC. Importantly, this work highlights the need
for further pathway analysis of metastatic tumours for overcoming drug resistance and developing new therapies.
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Introduction
Renal cell cancer (RCC) accounts for 2.5% of all adult cancers,
but it is the most lethal of all urological malignancies. One third of
RCC patients present with metastatic disease (mRCC). While
extirpative surgery is intended to be curative in those with localised
disease, a further 30–40% eventually develops distant metastases
[1,2,3]. At present, we are unable to accurately predict those
patients who will relapse, due to the highly variable natural history
of the disease.
Following surgery, a number of prognostic nomograms have
been proposed for predicting disease recurrence. These typically
include TNM staging and Fuhrman grade as well as performance
status and serum blood markers (haemoglobin, calcium, lactate
dehydrogenase, platelets, neutrophils and C-reactive protein) to
a greater or lesser extent [4,5,6,7]. These clinico-pathological
variables are widely used in clinical practice for stratifying risk of
recurrence and planning follow-up. Despite this, none of these
models are 100% accurate. In an attempt to improve patient’s risk
stratification, and better predict disease recurrence and associated
mortality, many have investigated the role of prognostic bio-
markers [8,9]. The EMT markers, SLUG and SNAIL, have been
reported to have predictive and prognostic importance in RCC
[10,11]. However, most notably, Klatte et al conducted an elegant
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study of key proteins in RCC pathogenesis using the TMA
technique to show Ki67, p53, vascular endothelial growth factor
receptor 1 (VEGFR1) and vascular endothelial growth factor
ligand D (VEGFD) were associated with disease free survival
(DFS) in localised RCC [12]. This panel of markers combined,
was able to better predict DFS compared to standard variables. A
prognostic nomogram was constructed combining these markers
with clinico-pathological variables for the first time showing an
improved predictive accuracy. Despite this, the routine use of these
markers in the clinic has not been adopted.
A better understanding of the molecular basis of RCC has not
only advanced biomarker discovery, but also advanced the
treatment of metastatic RCC (mRCC) with the development of
targeted molecular therapies. The most important discovery has
been the identification of mutations in the von Hippel-Lindau
(VHL) gene in hereditary clear cell RCC (ccRCC) and up to two-
thirds of sporadic cases [13]. This leads to activation of the
hypoxia pathway and the subsequent up-regulation of hypoxia
associated molecules i.e. vascular endothelial growth factors
(VEGF) and platelet derived growth factors. These discoveries
resulted in the clinical use of VEGF monoclonal antibody
(bevacizumab) and multi-targeted tyrosine kinase inhibitors
(sunitinib and sorafenib) in mRCC. Furthermore, understanding
of the role of the mammalian target of rapamycin (mTOR)
Figure 1. AQUA Images of renal cell carcinoma. Representative TMA core showing green cytoplasmic staining with a combination of
cytokeratin and pancadherin (A), blue nuclear staining with DAPI (B), red target staining (C, in this case VEGFR1) and all three compartments
combined (D). Quantitative assessment and compartment localisation of target expression is measured through calculating the sum of target pixel
intensity divided by the compartment area and normalized for exposure time.
doi:10.1371/journal.pone.0060483.g001
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pathway in RCC has given rise to the clinical use of mTOR
inhibitors, temsirolimus and everolimus. Despite the significant
improvement in efficacy compared to immunotherapies, the
previous gold standard for treatment of mRCC, resistance to
these molecular therapies remains a significant problem
[14,15,16].
Much of the knowledge of this molecular basis of RCC has been
uncovered through study of the primary renal tumour, with little
analysis of the differences between the primary tumour and the
metastases. Recently, Gerlinger et al reported that the genetic
signature of the primary tumour may not reflect that of the
metastasis [17], however there is little study of these differences at
the protein level. Lee et al have reported increased Bcl-2
expression [18] and Schultz et al have shown greater expression
of pAKT, pS6, 4EBP1 and cMYC and lower expression of PTEN
in the metastatic RCC compared with primary tumours [19]. It is
likely that the key to understanding resistance and developing
more effective treatments, is an in depth study of the metastatic
tumours, as the aim of treatment is to reduce the metastatic
tumour burden. Additionally, primary RCC tumour has a pre-
dilection to involve the venous system (renal vein, inferior vena
cava and right atrium), this venous tumour thrombus (VTT) is
potentially a middle ground between the phenotype of the primary
and metastatic tumour.
Immunohistochemistry (IHC) is a key tool in molecular
pathology used to aid diagnosis and prognosis in RCC. However,
IHC is subjective and only semi-quantitative. The development of
Automated Quantitative Analysis (AQUA) of immunofluorescence
allows accurate and sensitive in situ protein localisation and
quantification, which we have refined for use in RCC [11]. Briefly,
this involves immunofluorescent staining for the target protein and
to create an epithelial tumour mask, allowing differentiation of the
tumour from the stroma, and sub-localisation of the cytoplasm and
nuclei. There is subsequent digital image capture, and automated
analysis of the images to give continuous scores for target
expression. This technique allows greater objectivity and accuracy
of protein quantification and prognostication offered by Klatte and
colleagues. In this study we aim to use AQUA immunoflurescence
to assess the differential protein expression of reported prognostic
markers in primary tumour, VTT and metastases in RCC and
determine their prognostic role in locally advanced and/or
metastatic primary renal cell carcinoma.
Patients and Methods
Study Population
Patients who had primary renal cell carcinoma and/or renal
vein or inferior vena cava thrombus and/or distant RCC
metastases at the time of surgery or at a later date were identified
from a prospectively compiled database. Formalin fixed paraffin
embedded (FFPE) tumour samples were identified from 177 of
these patients who underwent radical nephrectomy between 1983
and 2010, in the Department of Urology, Edinburgh. Where
possible, written informed consent was gained for use of tissue
surplus to diagnostic requirement and linked anonymised patient
data. Ethical approval to use these archived tissues was granted by
the Lothian Regional Ethics Committee (08/S1101/41 and 10/
S1402/33). Ethical approval 08/S1101/41 permits the distribu-
tion of FFPE samples and associated linked anonymised data from
the Pathology archive for research without consent as they were
collected for diagnostic purposes prior to September 2006. The
diagnostic pathway for these tissue samples has now been
completed and the archived samples are surplus to this process.
Additional tissue from after 2006 was collected and released for
use under the ethical approval 10/S1402/33, which is Research
Tissue Bank ethical approval held by the SAHSC BioResource on
behalf of NHS Lothian. This approval applies the principles of
‘position statement on diagnostic archives releasing tissue for
research’ joint statement from the Human Tissue Authority (HTA)
and the National Research Ethics Service (NES) of July 2009 to
the use of these samples. All pathological staging was reported
using the TNM 2002 classification [20]. If causes of death were
not available in clinical notes these were obtained from the
General Registry Office of Scotland.
Tissue Microarray (TMA) Construction
These tissue samples were used to construct a TMA [21]. A
minimum of three representative replicate cores, 0.6 mm in
Table 1. Primary (target) antibodies used.
Antibody Catalogue number Species Dilution
Ki67 Dako M7240 Mouse 1:50
P53 Calbiochem OP43 Mouse 1:200
VEGFR1 Cell Signalling 2893s Rabbit 1:100
VEGFD Abcam ab95442 Rabbit 1:200
SNAIL Cell Signalling 3895 Mouse 1:50
SLUG Cell Signalling 9885 Rabbit 1:50
doi:10.1371/journal.pone.0060483.t001
Table 2. Clinico-pathological characteristics of primary renal
cell cancers.
Characteristic N %
Age Median years
(range)
64 (32–94)
Gender Male 96 59.6
Female 65 40.4
Laterality Left 60 51.7
Right 56 48.3
Mean tumour size(cm) 8.7 (1.5–16)
Histological Subtype Clear cell 135 88.8
Papillary 14 9.2
Other 3 2.0
pT Stage pT1a 6 4.1
pT1b 4 2.7
pT2 13 8.9
pT3a 11 7.5
pT3b 107 73.4
pT3c 1 0.7
pT4 4 2.7
Fuhrman Grade 1 3 2.8
2 41 38.3
3 46 43.0
4 17 15.9
Node Positive 29 15.8
Metastasis at diagnosis 13 7.1
doi:10.1371/journal.pone.0060483.t002
Differential Protein Expression in Renal Cancer
PLOS ONE | www.plosone.org 3 April 2013 | Volume 8 | Issue 4 | e60483
Figure 2. Differential nuclear Ki67 expression between primary, renal vein tumour thrombus and metastatic RCC. Significantly
increased expression of nuclear Ki67 shown in the metastases compared to the VTT and primary tumour but no difference in expression between the
primary tumour and the VTT.
doi:10.1371/journal.pone.0060483.g002
Figure 3. Differential nuclear p53 expression between primary, renal vein tumour thrombus and metastatic RCC. Significantly
increased expression of nuclear p53 shown in the metastases compared to the VTT and primary tumour but no difference in expression between the
primary tumour and the VTT.
doi:10.1371/journal.pone.0060483.g003
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Figure 4. Differential cytoplasmic VEGFR1 expression between primary, renal vein tumour thrombus and metastatic RCC.
Significantly increased expression of cytoplasmic VEGFR1 shown in the metastases compared to the VTT and primary tumour but no difference in
expression between the primary tumour and the VTT.
doi:10.1371/journal.pone.0060483.g004
Figure 5. Differential nuclear SNAIL expression between primary, renal vein tumour thrombus and metastatic RCC. Significantly
increased expression of nuclear SNAIL shown in the metastases compared to the VTT and primary tumour but no difference in expression between
the primary tumour and the VTT.
doi:10.1371/journal.pone.0060483.g005
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Figure 6. Differential nuclear SLUG expression between primary, renal vein tumour thrombus and metastatic RCC. Significantly
increased expression of nuclear SLUG shown in the metastases compared to the VTT and primary tumour but no difference in expression between
the primary tumour and the VTT.
doi:10.1371/journal.pone.0060483.g006
Figure 7. Kaplan Meier curve showing relationship of CSS with histological subtype. No significant difference in CSS is shown between
clear cell (n = 111) and papillary RCC (n = 11) tumours.
doi:10.1371/journal.pone.0060483.g007
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diameter, from each patient’s primary tumour, VTT and
metastases were taken after review and marking of the hematox-
ylin and eosin stained slides and blocks by a Consultant
Pathologist. Adequate tissue was not available from all primary
tumours and metastases. In total, 1980 cores were taken and
distributed over 12 slides from the 177 patients representing 163
primary tumours, 103 VTTs and 69 metastases. This included 29
patients with primary tumours only; 79 with matched primary and
VTTs; 24 with matched primary tumours, VTTs and metastases;
31 with matched primary tumours and metastases and 14 patients
with unmatched metastases only.
Immunofluorescence
TMA slides were de-waxed in xylene and then rehydrated in
sequentially dilute ethanol solutions. Antigen retrieval was
conducted by heating the slides in a pressure cooker for 5 minutes
in Tris-EDTA pH9.0 or Sodium Citrate pH6.0. Endogenous
peroxidase activity was blocked by treating the slides in 3%
hydrogen peroxide for 10 minutes and non-specific binding
reduced by incubation in serum-free protein block (Dako, X0909)
for 10 minutes. Slides were incubated with the primary target
antibody, for the protein of interest, for 1 hour at room
temperature. Primary antibodies are detailed in table 1. Thereafter
the slides were incubated overnight at 4uC with the appropriate
antibodies to define the tumour mask. These were pan-cadherin
(Cell Signalling, 4068, 1:100) when using a rabbit primary
antibody or a combination of pan-cadherin (Sigma-Aldrich,
C1821, 1:750) and CK5/6/8/18 (Novocastro, 6003168, 1:100)
when using a mouse primary antibody [11]. The slides were then
incubated for 1.5 hours with Alexa Fluor 555-conjugated antibody
(Invitrogen A21422 and A21428, 1:25) and horseradish peroxi-
dase–decorated dextran-polymer backbone antibody (EnVision,-
Dako). Slides were then incubated for 10 minutes with Cy5-
Tyramide (HistoRx, AQUAntiplex tube F, 1:50), which activated
the horseradish peroxidase and allowed visualisation of the
primary antibody. DAPI (49, 6-diamidino-2-phenylindole, Invitro-
gen, P36931) counterstain was used to visualise the nuclei. A
representative core is seen in figure 1.
Automated Quantitative Analysis
Monochromatic images of each TMA core were captured at
206 objective using an Olympus AX-51 epifluorescence micro-
scope (Olympus, Pennsylvania, USA). If the epithelium comprised
less than 5% of the total core area, the core was excluded from
analysis. High-resolution digital images were analysed by the
AQUAnalysis software (HistoRx, Conneticut, USA), to determine
Figure 8. Kaplan Meier curve showing relationship of CSS with pathological tumour stage. CSS was statistically different based on
pathological tumour stage on Kaplan Meier analysis. 122 patients were included in this analysis (7 pT stage 1, 13 pT stage 2, 99 pT stage 3 and 3 pT
stage 4), others were excluded due incomplete follow-up or pathology data. This shows poorer CSS with worsening pathological tumour stage at
diagnosis.
doi:10.1371/journal.pone.0060483.g008
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Figure 9. Kaplan Meier curve showing relationship of CSS with Fuhrman grade. This shows statistically different CSS based on Fuhrman
grade. 89 patients were included in this analysis (1 grade 1, 35 grade 2, 38 grade 3 and 15 grade 4), others were excluded due incomplete follow-up
or pathology data. There is poorest CSS for grade 1, with indistinguishable CSS for grade 3 and 4, and most favourable CSS for grade 2.
doi:10.1371/journal.pone.0060483.g009
Figure 10. Kaplan Meier curve showing relationship of CSS with node status at diagnosis. Positive node status at diagnosis has
significantly worse CSS than node negative disease.
doi:10.1371/journal.pone.0060483.g010
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target protein expression overall and in the cytoplasmic and
nuclear compartments by calculating the sum of target pixel
intensity divided by the compartment area and normalized for
exposure time.
Statistical Analysis
Appropriate compartment AQUA scores were normalised by
median centring for each TMA to allow inter-TMA comparisons
and then the mean tissue score taken from replicate cores. X-tile
was used for determining the cut off for defining high and low
protein expression in the primary tumour, for Kaplan Meier
Figure 11. Kaplan Meier curve showing relationship of CSS with cytoplasmic VEGFR1. High VEGFR1 expression in the primary tumour is
related to significantly worse CSS than low VEGFR1 expression.
doi:10.1371/journal.pone.0060483.g011
Figure 12. Kaplan Meier curve showing relationship of CSS with cytoplasmic VEGFD. High VEGFD expression in the primary tumour is
related to significantly worse CSS than low VEGFD expression.
doi:10.1371/journal.pone.0060483.g012
Differential Protein Expression in Renal Cancer
PLOS ONE | www.plosone.org 9 April 2013 | Volume 8 | Issue 4 | e60483
analysis [22]. Cancer specific survival (CSS) was determined by
Kaplan Meier analysis and comparisons made by log-rank test.
Predictive significance of protein expression and clinico-patholog-
ical factors for CSS was determined using Cox univariate and
multivariate regression analysis. Correlation of protein expression
with standard pathological factors was assessed with Pearson
correlation analysis. Differential protein expression between the
primary tumour, renal vein tumour thrombus and metastatic
tissue was assessed using the Mann-Whitney test. Statistical
analysis was performed using PAWS version 18.0 (SPSS Inc.,
Chicago, IL, USA), p,0.05 was taken to indicate significance.
Results
The clinico-pathological features associated with the patients’
primary RCC are shown in Table 2. The median patient age was
64 years and the male to female ratio was 1.5:1. There was no
significant difference in the laterality of tumours and the mean
tumour size was 8.7 cm (range: 1.5–16 cm). The majority of
tumours (n = 138; 88%) were histologically clear cell, while 14
(9.8%) were papillary and the remainder were other rarer
subtypes. Most cases were pathological stage T3b (n= 107,
73.4%). 29 (15.8%) cases were pathologically node positive at
time of nephrectomy and 13 (7.1%) patients had confirmed
metastases at initial diagnosis.
Ki67 and p53 expression was not identified above background
levels in 35.8% (n= 59) and 1.2% (n= 2) of primary RCCs
respectively. Otherwise protein expression of the other markers
was identified in all tumours. Assessment of the relationship
between protein expression in the primary tumour and standard
pathological parameters revealed increased SNAIL expression
correlated with advanced pathological tumour stage (p= 0.001)
and increased maximum tumour diameter (p = 0.048). High
VEGFR1 and VEGFD were associated with non-clear cell
subtype (p= 0.017 and p= 0.018 respectively).
Furthermore, high VEGFR1 in the complete tumour mask, but
not in the localised cytoplasmic compartment, was correlated with
node positive disease (p = 0.005). There were no other significant
correlations between assessed protein expression and standard
clinico-pathological variables.
Assessment of differential protein expression between the
primary tumour, VTT and the metastases revealed no significant
difference between the primary tumour and VTT but significantly
increased expression in the metastases compared to the primary
and VTT for Ki67, p53, VEGFR1, SNAIL and SLUG (Figures 2,
3, 4, 5, 6). Accurate survival data was available for 132 patients.
Mean follow-up time was 58 months. Histological subgroup did
not significantly influence CSS on Kaplan Meier analysis;
however, pathological tumour stage (pT stage), Fuhrman grade
and node positive disease at diagnosis did predict CSS (figures 7, 8,
9, 10). Survival analysis of the proteomic markers revealed high
VEGFR1 and VEGFD to be associated with significantly lower
CSS (figures 11 & 12). There was no significant difference in CSS
with Ki67, p53, SNAIL and SLUG expression level. Median,
predicted 5 and 10 year survival for the pathological variables and
proteomic markers are detailed in tables 3 and 4 respectively.
Those variables which were significant in Kaplan Meier analysis
were assessed with Cox multivariate regression analysis, and the
clinical variables of Fuhrman grade and node status remained
significant, while pT stage, VEGFR1 and VEGFD were not
independently prognostic (Table 5).
Discussion
This novel study has demonstrated significantly increased
expression of Ki67, p53, VEGFR1, SLUG and SNAIL in RCC
metastases, compared to the primary tumour and the venous
tumour thrombus. Furthermore, primary tumour expression of
VEGFR1 and VEGFD can be used to predict significant
differences in cancer specific survival in advanced renal cell
carcinoma. While VEGFR1 and VEGFD were significant on
univariate analysis, superior independent prognostic significance
of these markers over standard clinico-pathological parameters in
multivariate analysis could not be shown.
To our knowledge, this is the largest reported series of primary
and metastatic RCC samples used to construct a TMA for
comparative protein analysis, and is the only study to assess the
VTT at a molecular level. Additionally, the use of AQUA
immunofluorescence allows more accurate and objective protein
quantification, an improvement on other published work studying
protein expression using the TMA technique. However, we
acknowledge this unique and difficult to acquire tissue set still
represents a small cohort. This may give rise to type II errors as
a result of an underpowered study. In particular this may have
prevented significant differences between the primary tumour and
VTT protein expression being detected and potential underesti-
Table 3. Histological parameters associated cancer specific survival.
Histological parameter P-value Median 5 yr survival 10 yr survival
Histological subtype Clear cell 0.115 64.0 52.4 39.8
Papillary 258.0 79.5 59.7
pT stage* 1 0.032 127.0 85.7 64.3
2 141.0 53.3 58.3
3 64.0 50.2 35.6
4 5.0 33.3 –
Fuhrman Grade* 2 0.002 141.0 71.8 59.6
3 33.0 45.4 27.7
4 33.0 36.0 –
Node Status* Negative ,0.001 92.0 60.1 43.7
Positive 11.0 28.2 9.4
*highlights significant variable.
doi:10.1371/journal.pone.0060483.t003
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mation of the prognostic significance of these markers and known
pathological prognostic indicators, especially in multivariate
analysis. The markers chosen were based on previously docu-
mented prognostic significance, implicating their importance in
RCC pathogenesis, however it would be important in the future to
perform a large scale unbiased assessment of proteins to assess the
scale of difference between primary and metastatic RCC.
Nonetheless, significant differences in protein expression of key
markers between the primary tumour and metastasis have been
shown for the first time.
The difference in Ki67 expression between primary and
metastatic lesions has been studied in a number of cancers
including breast, colon, gastrointestinal stromal (GIST) and
bladder cancer, with contrasting results. In breast and colorectal
cancer, higher Ki67 expression in primary tumours compared
with nodal and liver metastases respectively, was shown
[23,24,25,26]. However, in GIST and bladder tumours, as well
as other studies of breast and colorectal carcinoma, the converse or
no difference in expression has been demonstrated [27,28,29,30].
The results of the present study have shown a significant increase
in Ki67 expression in metastatic RCC tissue compared to primary
and VTT RCC, suggesting up regulation of proliferation, which
has not been reported previously. Others however have in-
vestigated differential p53 expression in primary and metastatic
RCC [31,32,33]. Due to the extended half-life of mutant p53
compared with wild type p53, mutant rather than wild type p53 is
detected with immunohistochemistry [33]. Our work has con-
firmed the increased expression of mutant p53 in metastatic RCC
shown previously, implicating inactivation of p53 in disease
progression.
This study has also demonstrated for the first time, increased
expression of VEGFR1 in metastatic compared to primary and
VTT RCC tissue. VEGF is an important signalling protein
involved in angiogenesis and lymphangiogenesis [34], key pro-
cesses in cancer growth and dissemination; hallmarks of cancer
[35]. The up regulation of VEGF through the induction of the
hypoxia pathway with mutation of the VHL gene is well accepted
in the pathogenesis of ccRCC and has led to the successful
development of molecular therapies in the treatment of RCC.
However, differential VEGF and VEGFR expression in primary
and metastatic RCC has not previously been studied, despite the
RCC metastases being the target of VEGF inhibitors. Increased
VEGF (rather than VEGFR) mRNA levels were seen in liver
metastases compared to primary colorectal tumours [36], while no
difference in protein expression of VEGF or VEGFR1 in
melanoma and paired metastases has been reported [37]. Our
results have confirmed increased expression of VEGFR1 in
metastatic RCC, implicating up regulation of angiogenesis and
lymphangiogenesis, and supporting the use of VEGF targeted
therapies in metastatic disease.
Activating invasion and metastasis is another hallmark of cancer
[35] and epithelial to mesenchymal transition (EMT) is thought to
be an important process in this, in which a physiological
developmental process is reversed. Sarcomatoid de-differentiation
is seen in RCC [38,39], and this may be a phenotypic example of
EMT observed by the pathologist. We have shown significantly
greater expression of both SLUG and SNAIL proteins in
metastatic RCC compared to the primary tumours, as well as
a correlation between increased SNAIL expression and increasing
tumour size and advancing pT stage. This supports the de-
velopment of an EMT phenotype at a molecular level in RCC
pathogenesis.
This work so far has indicated key proteins may be important in
the pathogenesis of RCC and shown significant differences in the
protein expression in primary and VTT RCC compared to the
metastatic deposits. We hypothesised that the VTT would be an
intermediate process between the primary and metastases but were
unable to demonstrate this with the proteins assessed. This may be
as a result of a number of factors. Firstly, as previously indicated
this remains a relatively small cohort, and as such may be
underpowered. It is a possibility that the proteins studied are not
key to the invasive extension of the primary into a VTT. However,
one would intuitively expect markers of proliferation, angiogenesis
and EMT to be involved in such a process. Finally, we must accept
that a tumour which migrates, adapts and grows in a new
environment is different from a tumour which invades locally, and
that the VTT may be more representative of an extension of the
primary tumour.
As well as differential protein expression, we aimed to assess the
prognostic significance of these markers in advanced RCC. We
found standard pathological factors remain the most significant
variables in predicting cancer specific survival. Nodal disease at
presentation has been shown to be prognostic in both otherwise
localised disease and metastatic disease independent of other
prognostic factors [40,41,42]. We have confirmed the significance
of this pathological finding in the current study, where positive
Table 4. Protein related cancer specific survival.
Protein
Expression
level p value Median
5 yr
survival
10 yr
survival
Ki67 Low 0.195 72.0 56.3 39.2
High 25.0 33.6 25.2
p53 Low 0.237 69.0 59.8 39.4
High 33.0 42.8 32.1
VEGFR1* Low 0.011 113.0 64.2 46.9
High 33.0 39.5 19.2
VEGFD* Low 0.003 72.0 59.4 44.2
High 25.0 36.5 15.2
SNAIL Low 0.714 127.0 62.1 51.1
High 62.0 50.7 33.5
SLUG Low 0.205 72.0 60.8 35.6
High 53.0 47.7 36.4
*highlights significant variable.
doi:10.1371/journal.pone.0060483.t004
Table 5. Cox multivariate regression analysis of proteomic
and clinico-pathological factors in cancer specific survival
found to be significant on Kaplan Meier analysis.
Variables P value
Hazard
Ratio
95% Confidence
Intervals
Lower Upper
cytoplasmic VEGFR1 0.485 1.3 0.66 2.38
cytoplasmic VEGFD 0.124 1.7 0.87 3.28
Fuhrman Grade* 0.036 1.6 1.03 2.50
pT stage 0.146 1.7 0.83 3.46
Node status at diagnosis* 0.009 2.6 1.27 5.44
*highlights significant variable. Confirming Fuhrman grade and node status to
be independently significant on multivariate analysis of predictors of CSS.
doi:10.1371/journal.pone.0060483.t005
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nodal involvement has the greatest hazard ratio (2.7) on
multivariate analysis for CSS.
Fuhrman grade was also found to be significant on univariate
and multivariate analysis. Fuhrman grade is based on the
assessment of nuclear size, nuclear pleomorphism, and nucleolar
prominence [43] and while its prognostic significance in papillary
and chromophobe RCC is debated [44] it has been clearly shown
to be important in ccRCC [43,45,46,47]. In our analysis,
Fuhrman grade 1 had the poorest prognosis and this is likely
due the small sample size, while grade 2 disease had significantly
prolonged CSS compared with grade 3 and 4, which were
indistinguishable. The comparable CSS of patient with Fuhrman
grade 3 and 4 disease may be the result of other confounding
factors; however, there is currently concern regarding intra- and
inter-pathologist reporting variability of Fuhrman grade [44]
which has led to the International Society of Urological Pathology
(ISUP) recommending replacing Fuhrman grading with ISUP
nucleolar grading system, based solely on the nucleolar size as
outlined in Fuhrman but without the confounding and confusing
issues of nuclear size and shape.
Pathological tumour stage was significant on Kaplan Meier
analysis but not multivariate analysis. The small sample size of
stages other than pT3, and the high risk nature of the cohort,
selected because of renal vein involvement and/or concurrent or
subsequent metastases, have prevented identification of the
prognostic role of tumour stage clearly identified in localised
disease [4,37,45,46]. The small sample size of non-clear cell RCC
may also have prevented any significant difference in CSS being
identified based on histological subtype (likely type II error),
although there was a clear trend of lower CSS with ccRCC.
The prognostic significance of Ki67 and p53 expression has
been widely studied in RCC. The proliferation marker, Ki67, has
been shown to be associated with higher nuclear grade and worse
prognosis in localised ccRCC [12] and mRCC [48]. However,
other studies in localised RCC have failed to demonstrate the
independent prognostic significance of Ki67, largely because of its
close association with tumour grade and stage [49,50]. Our study
of locally advanced and metastatic RCC, although showing a trend
of poorer prognosis in higher Ki67 expression, failed to
demonstrate any significant difference in CSS based on Ki67
expression. Similarly, the prognostic significance of p53 in RCC is
also debated [32,50,51,52,53,54,55,56], and in our cohort no
difference in CSS was seen between high and low expression.
Gene expression studies in RCC have shown an EMT signature to
be associated with poorer prognosis [57,58]. Despite these
findings, quantitative assessment of SNAIL and SLUG, key
proteins in EMT, failed to show any significant difference in CSS.
VEGF expression has also been investigated in RCC by others
and found to be prognostic. In particular, VEGFR1 has been
found to be associated with worse outcome in localised RCC [12],
and our study has confirmed this on univariate analysis in
advanced disease. Others have suggested low VEGFD to be
associated with worse prognosis [1,12], however we have seen the
converse in advanced disease with poorer outcome associated with
higher VEGFD in the primary tumour and we propose this is
likely to be the result of up regulation of lymphangiogenesis.
However, the loss of significance of these markers in multivariate
analysis may be as a result of the very role of VEGF in
lymphangiogenesis discussed. This is supported by the correlation
between VEGFR1 and node positive disease with the resultant
dominant effect of lymph node metastasis in predicting prognosis.
The present study also correlated VEGFR1 and VEGFD with
histological subtype, revealing greater expression in pRCC than
ccRCC. VEGF expression with histological subtype of RCC is
controversial. Ljungberg et al studied VEGF and receptor status at
the transcriptional level and found higher levels in ccRCC
compared with pRCC [59]. It was proposed that this was as
a result of the VHL mutation, common in ccRCC but rare in
other subgroups, with up regulation of HIF, which has been
reported to be greater in ccRCC than other subtypes [60,61].
However, a proteomic study by Jacobsen et al failed to show any
difference in VEGF expression between histological subgroups
[62], while Dirim et al identified higher VEGF in pRCC
compared with ccRCC [63]. There was no significant difference
in tumour size, grade or stage between subgroups that may be
attributable to the difference found in this study (data not shown).
It has been reported that pRCCs are hypovascular, and it is
possible that this increase in VEGF is a reflection of the hypoxic
microenvironment of the tumour [64]. Our finding further
strengthens the importance of VEGF and angiogenesis in pro-
gression of RCC and supports the efficacy of angiogenesis
inhibitors in all RCC, including non-clear cell subtypes [65].
Although unable to show the independent prognostic signifi-
cance of selected key proteins above standard pathological
parameters in locally advanced RCC, the significance of VEGFR1
and VEGFD on univariate analysis confirms the importance of the
hypoxia pathway in RCC pathogenesis. The difference in Ki67,
p53, VEGFR1, SLUG and SNAIL between the primary tumour
and metastases highlights the importance of proliferation, angio-
genesis and EMT in RCC pathogenesis also. We propose greater
analysis of the differences between primary tumours and
metastases is required to gain a full appreciation of the pathway
changes, as these differences may have implications for future
work understanding the response to treatment in metastatic
disease and overcoming resistance.
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